Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7741 USD | -0.78% | -2.67% | -44.71% |
Evolution of the average Target Price on Seres Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Seres Therapeutics, Inc.
Oppenheimer | |
Chardan Research | |
Goldman Sachs | |
JPMorgan Chase | |
Canaccord Genuity | |
Piper Sandler | |
HC Wainwright | |
Chardan |
EPS Revisions
- Stock
- Equities
- Stock Seres Therapeutics, Inc. - Nasdaq
- Consensus Seres Therapeutics, Inc.